Dose Escalation Trial of BNT152+153 in Patients With Cancer
← catalyst calendarSponsored by BioNTech SE (industry) · BNTX — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
86actual
Sites
7
Countries
Czechia, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-06-08 | actual | When the study began enrolling |
| Primary completion | 2025-09-10 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-09-10 | actual | The whole study's end, after follow-up |
| First posted | 2021-01-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-09-25 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Solid Tumor
Interventions
- Drug: BNT152
- Drug: BNT153
Primary outcomes
what the primary-completion date above is the date OFOccurrence of treatment-emergent adverse events (TEAEs) including Grade ≥ 3, serious, fatal TEAE by causal relationship to trial treatment
measured up to 24 months
Occurrence of dose reduction and discontinuation of investigational medicinal product within a patient due to TEAE
measured up to 24 months
Occurrence of dose limiting toxicities (DLTs) during the DLT evaluation period - BNT152
measured 21 days
Occurrence of DLTs during the DLT evaluation period - BNT153
measured 21 days
Permalink · BNTX's whole pipeline · Catalyst calendar · Every registered study · What changed